【腫瘤】《Lantern: LTRN》AI新藥LP-184對第一位「晚期實體固態腫瘤」進行第一期臨床

 【腫瘤】《Lantern: LTRN》AI新藥「LP-184」對第一位「晚期實體固態腫瘤」病患進行第一期臨床試驗

 文章出處  

 Businesswire

 

 原文標題  

Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors 

 

 Twitter  

https://twitter.com/aimedadviser/status/1706473698000244820 

 

 文章序號  

4392 

 

智醫科學－AI醫療技術、應用與市場動態

Copyright ©2023 智醫科學 MEDai.tw All rights reserved.

The content of this site is intended for healthcare and medical professionals.